Modest Money | Jun 30, 2016 01:52AM ET
MannKind Corporation (NASDAQ:MNKD)
MannKind has had an incredibly hard time in the market over the past year or so, and for good reason. The first launch of the company’s flagship product, Afrezza, simply didn’t go well. So, I can understand why many investors and traders would be hesitant to get involved in the stock. Nonetheless, Afrezza Launch 2.0 start in July, and it will likely create big gains. Today, we’ll talk about why the first launch of the treatment didn’t go well, why I’m expecting the second launch to go great, and what kind of opportunity lies ahead for MNKD. So, let’s get right to it…
h2 Why The First Launch Of Afrezza Brought MNKD Downward/h2As mentioned above, the first launch of Afrezza simply wasn’t a good one. However, it’s important to understand that it wasn’t MannKind’s fault. When the company received the news of approval from the United States FDA, the first thing they did was contract the commercialization of the treatment out. The problem was who the contract was signed with.
Shortly after the approval of Afrezza, MNKD signed a contract with Sanofi (PA:SASY). Unfortunately, Sanofi had a competing insulin. Therefore, there was a bit of a conflict of interests here. While Sanofi would make some money if Afrezza took off like a rocket, the action would cause lost earnings potential on their own product. In the long run, it was better for Sanofi if Afrezza didn’t do well.
So, for about a year, we heard that the next big part of commercialization would be coming soon. However, it never seemed to come. At the end of the day, Sanofi bombed the commercialization process, dragging its feet the entire way. As a result, MNKD saw massive declines in the value of its stock.
h2 Why The Second Launch Is Likely To Go Quite A Bit Better/h2While the first launch of Afrezza didn’t go very well, the second launch will likely be a hit. The truth is that there are several differences between the two. Here are some of the most important…
Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from MNKD. The reality is that the company has come up with an incredible treatment that has an inherent need in the diabetic community. Now, with a clear focus on commercialization, we’re likely to see sales of this product climb. As a result, I’m expecting to see big gains in revenue, leading to profits. When it comes to MannKind, there is tremendous upside potential here.
h2 What Do You Think?/h2Where do you think MNKD is headed moving forward and why? Join the discussion in the comments below!
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.